Cantor Fitzgerald Maintains Overweight on Taysha Gene Therapies, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and increased the price target from $6 to $7.
November 15, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reaffirmed an Overweight rating on Taysha Gene Therapies and raised the price target to $7, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, suggesting that the analyst sees potential for the stock's price to rise. This can often lead to increased investor confidence and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100